Breast cancer chemoprevention: The saga of underuse continues

Journal of the National Cancer Institute

Volumn 107, Issue 1, 2015, Pages

  Wickerham, D Lawrence ^a,b   Vogel, Victor G ^a,c  

^a NSABP Foundation Inc   (United States)

^b ALLEGHENY GENERAL HOSPITAL   (United States)

^c GEISINGER HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EXEMESTANE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; ANTIESTROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

AFRICAN AMERICAN; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; EDITORIAL; ENDOMETRIUM CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HISPANIC; HUMAN; MEDICATION COMPLIANCE; NON PROFIT ORGANIZATION; PATIENT HISTORY OF HYSTERECTOMY; POSTMENOPAUSE; PRACTICE GUIDELINE; PREMENOPAUSE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK REDUCTION; BREAST NEOPLASMS; FEMALE; PROCEDURES;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; PRIMARY PREVENTION; TAMOXIFEN;

EID: 84925546216     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju399     Document Type: Editorial

References (9)

1. Siegel R, Ma J, Zou Z, Jemal J. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29.
2. Ravdin PM. The lack, need, and opportunities for decisionmaking and informational tools to educate primary-care physicians and women about breast cancer chemoprevention. Cancer Prev Res. 2010;3(6):686-688.
3. Nichols HB, DeRoo LA, Scharf D, Sandler DP. Risk-benefit profiles of women using tamoxifen for chemoprevention. J Natl Cancer Inst. 2014;107(1):dju354 doi:10.1093/jnci/dju354.
4. Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 1999;91(21):1829-1846.
5. Vogel VG, Costantino JP, Wickerham DL, Cronin WM. Re: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 2002;94(19):1504.
6. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA. 2006;295(23):2727-2741.
7. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371-1388.
8. Freedman AN, Yu B, Gail MH, et al. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol. 2011;29:2327-2333.
9. Visvanathan K, Hurley P, Bantug E, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2013;31(23):2942-2962.